Evaluate the Safety Profile of BGF MDI in Chinese Patients with COPD in Routine Clinical Practice

Trial Identifier: D5980R00016
Sponsor: AstraZeneca
NCTID:: NCT04536402
Start Date: March 2021
Primary Completion Date: November 2023
Study Completion Date: November 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Beijing, China, 100070
China Changzhi, China, 046000
China Chengdu, China
China Chengdu, China, 610016
China Chifeng, China
China Chongqing, China
China Guangyuan, China
China Guangzhou, China, 510150
China Guangzhou, China, 510120
China Guangzhou, China, 510620
China Haikou, China, 570311
China Haikou, China
China Haining, China
China Hangzhou, China
China Hangzhou, China, 310005
China Huizhou, China
China Jiaxing, China
China Jinan, China, 250012
China Jinhua, China, 321000
China Jinzhong, China, 030600
China Mianyang, China, 621000
China Nanjing, China, 211100
China Nanjing, China, 223800
China Shanghai, China, 200433
China Shenzhen, China, 518039
China Shenzhen, China, 518100
China Shenzhen, China, 518055
China Taizhou, China, 317000
China Taizhou, China, 318000
China Weifang, China, 261041
China Wuxi, China, 214002
China Xian, China, 710100
China Xian, China, 710000
China Xinxiang, China
China Xinzheng, China, 451100
China Yangquan, China, 045000
China Yinchuan, China
China Zhengzhou, China
China Zibo, China